Pluvicto®▼ (lutetium [177Lu] vipivotide tetraxetan) is indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy or who are not medically suitable for taxanes.1
Resources
Resources for patients
Pluvicto patient booklet
To be shared with adult patients in the UK who have been prescribed Pluvicto for their PSMA-positive mCRPC or for whom the prescribing decision has been made.
This booklet does not replace the patient information leaflet (PIL) that comes with Pluvicto or advice from the patient’s healthcare team.
Pluvicto patient treatment card
To be shared with adult patients in the UK who have been prescribed Pluvicto for their PSMA-positive mCRPC or for whom the prescribing decision has been made.
This treatment card does not replace the patient information leaflet (PIL) that comes with Pluvicto or advice from the patient’s healthcare team.
AR, androgen receptor; mCRPC, metastatic castration-resistant prostate cancer; PSMA, prostate-specific membrane antigen.
Reference:
- Pluvicto®▼ (lutetium [177Lu] vipivotide tetraxetan) Summary of Product Characteristics.